TScan Therapeutics Future Growth
Future criteria checks 2/6
TScan Therapeutics's earnings are forecast to decline at 7.6% per annum while its annual revenue is expected to grow at 39.3% per year. EPS is expected to decline by 0.9% per annum.
Key information
-7.6%
Earnings growth rate
-0.9%
EPS growth rate
| Biotechs earnings growth | 24.6% |
| Revenue growth rate | 39.3% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 16 May 2024 |
Recent future growth updates
Recent updates
Subdued Growth No Barrier To TScan Therapeutics, Inc.'s (NASDAQ:TCRX) Price
Mar 23
Is TScan Therapeutics (NASDAQ:TCRX) Using Too Much Debt?
Feb 17TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target
Mar 11TScan Therapeutics GAAP EPS of -$0.63 beats by $0.13, revenue of $4.05M beats by $1.05M
Aug 10TScan Therapeutics appoints Debora Barton as Chief Medical Officer
Jul 07Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation
May 22Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?
Jan 17We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate
Oct 18Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 5 | -162 | -118 | -135 | 4 |
| 12/31/2025 | 6 | -151 | -111 | -118 | 5 |
| 12/31/2024 | 7 | -131 | -94 | -90 | 4 |
| 3/31/2024 | 15 | -97 | -70 | -67 | N/A |
| 12/31/2023 | 21 | -89 | -65 | -61 | N/A |
| 9/30/2023 | 17 | -88 | -58 | -54 | N/A |
| 6/30/2023 | 16 | -82 | -82 | -79 | N/A |
| 3/31/2023 | 17 | -73 | -74 | -70 | N/A |
| 12/31/2022 | 14 | -66 | -71 | -67 | N/A |
| 9/30/2022 | 13 | -62 | -70 | -65 | N/A |
| 6/30/2022 | 12 | -61 | -67 | -62 | N/A |
| 3/31/2022 | 11 | -57 | -66 | -59 | N/A |
| 12/31/2021 | 10 | -49 | -59 | -49 | N/A |
| 9/30/2021 | 8 | -42 | -51 | -42 | N/A |
| 6/30/2021 | 6 | -34 | -43 | -34 | N/A |
| 3/31/2021 | 3 | -29 | -14 | -8 | N/A |
| 12/31/2020 | 1 | -26 | -7 | -3 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TCRX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TCRX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TCRX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TCRX's revenue (39.3% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: TCRX's revenue (39.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TCRX's Return on Equity is forecast to be high in 3 years time